Goodrx Holdings Inc

1. 1

   Election of Directors

   ManagementBoard: FOR

   Elect Wendy Barnes, Ronald E. Bruehlman and Gregory Mondre as Class III Directors to serve until the 2029 Annual Meeting.

2. 2

   Ratification of Appointment of Independent Registered Public Accounting Firm

   ManagementBoard: FOR

   Ratify the Audit & Risk Committee’s appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

3. 3

   Advisory (Non-Binding) Approval of Named Executive Officer Compensation (Say-on-Pay

   ManagementBoard: FOR

   Approve, on an advisory (non-binding) basis, the compensation of the Company’s named executive officers as disclosed in the proxy (say-on-pay).

   More detail

   This advisory proposal asks shareholders to approve, on a non-binding basis, the Company’s executive compensation program as described in the proxy, including the Compensation Discussion and Analysis, compensation tables and narrative. Management is seeking shareholder support to validate its pay practices, which it says are designed to attract, motivate and retain senior executives and align their interests with long-term stockholder value via a mix of base salary, performance-based annual cash incentives, and equity awards (stock options, RSUs, and newly introduced performance-based RSUs). The proxy discloses specific 2025 decisions that provide context: annual bonus metrics tied to Adjusted EBITDA Margin and Revenue (with a funding gate), no corporate bonus payout for most NEOs in 2025 due to not meeting revenue thresholds, large new-hire and retention awards in 2025 (including signing bonuses and $2.0M/$1.0M retention bonuses for the CEO and CFO, respectively), and substantial equity grants to align executives’ incentives with long-term performance. The vote is advisory and non-binding, but the Board and Compensation Committee state they value stockholder feedback and will consider the results when reviewing compensation policies. The Company also states it holds an annual say-on-pay vote (consistent with the 2022 stockholder recommendation) and will continue to do so, with the next advisory vote expected in 2027. Management’s counter-argument to potential criticism emphasizes governance practices: use of an independent compensation consultant, pay-for-performance linkages, stock ownership guidelines, clawback policy, and no excise tax gross-ups, with the Compensation Committee retaining discretion to adjust awards. Given recent leadership transitions, retention payments, and equity award practices disclosed in the proxy, the proposal is a focal point for stockholder scrutiny about balancing retention and pay-for-performance; a sophisticated reviewer should weigh the disclosed performance metrics and pay outcomes, the non-binding nature of the vote, and the company’s governance safeguards when assessing the merits of supporting the Board’s recommendation.

Upcoming shareholder meetings at Goodrx Holdings Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.

When is the Goodrx Holdings Inc 2026 annual meeting?

Goodrx Holdings Inc (GDRX) holds its 2026 annual shareholder meeting on Tuesday, June 16, 2026.

What is the record date for the Goodrx Holdings Inc 2026 meeting?

The record date for the Goodrx Holdings Inc 2026 meeting is Monday, April 20, 2026. Shareholders of record on or before that date are eligible to vote.

Who are the director nominees for Goodrx Holdings Inc's 2026 meeting?

The board is presenting 3 director nominees at the Goodrx Holdings Inc 2026 meeting, listed with their independence status and background.

What proposals will shareholders vote on at the Goodrx Holdings Inc 2026 meeting?

Shareholders will vote on 3 proposals at the Goodrx Holdings Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.